The hunt for CJC-1295 in Exira reliably produces the same conclusion: research peptides are distributed through specialist online vendors, not local retail. What this means for Exira researchers is that physical proximity is irrelevant compared to your ability to verify analytical documentation — and those verification methods are within reach of all serious researchers. Separating properly characterised CJC-1295 from the rest of the market depends on three things: an HPLC chromatogram showing ≥98% purity, mass spec data establishing the correct molecular weight, and a batch-specific endotoxin panel. What follows is a practical research guide built specifically around CJC-1295, covering everything a Exira researcher needs to evaluate quality systematically.
The Science Behind CJC-1295
CJC-1295 belongs to the growth hormone secretagogue (GHS) class, compounds that stimulate pulsatile growth hormone release by acting on the ghrelin receptor (GHSR-1a) or growth hormone releasing hormone (GHRH) receptor. Ipamorelin, GHRP-2, GHRP-6, and Hexarelin all work primarily through GHSR-1a agonism, producing GH pulses with varying specificity profiles. CJC-1295 and Sermorelin work through the GHRH receptor, mimicking the natural hypothalamic signal for GH release. The downstream effect in both cases is increased pulsatile GH secretion and subsequent IGF-1 production in the liver. For researchers in Exira studying the GH-IGF-1 axis, this mechanistic clarity makes the GHS class a productive experimental tool.
How to Evaluate CJC-1295 Vendors
Vetting CJC-1295 vendors begins with the COA: request the batch-specific certificate prior to buying, not after. The HPLC chromatogram is the most important document in the COA: it should show a large primary peak representing CJC-1295, with small or absent impurity peaks representing impurities — purity should be 98% or higher. Red flags in CJC-1295 vendor evaluation: prices significantly below market average, no information about manufacturing source, no community presence, and COAs that do not include endotoxin results. For Exira researchers making a first CJC-1295 purchase: work through this evaluation framework first, order conservatively at first, and check that batch numbers on your vial match the COA before use.
Order CJC-1295 — ships to Exira
COA-verified · International tracking · Research grade
CJC-1295 is available for research use only and is not approved for human therapeutic use by the FDA or equivalent agencies worldwide — all information here is educational. Reconstitute CJC-1295 with bacteriostatic water at a concentration matched to your dosing requirements; a standard 5mg reconstituted in 2mL produces 2.5mg/mL — or 25mcg per insulin syringe unit. The primary quality-related safety risk in CJC-1295 research is endotoxin contamination from poor sourcing — a documented endotoxin result in your specific batch certificate is the key safeguard. The research literature on CJC-1295 should be studied thoroughly before beginning any research — study designs, dosing ranges, and outcome measures vary significantly and not all findings translate directly.
Frequently Asked Questions
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
